Baidu
map

AHA、ADA 联合发布2型糖尿病患者心血管疾病预防的新指南

2015-08-13 MedSci MedSci原创

AHA、ADA 联合发布2型糖尿病患者心血管疾病预防的新指南近日,美国糖尿病学会(ADA)和美国心脏协会(AHA)联合发布了新修订的成人2型糖尿病患者心血管疾病预防的科学指南 。该指南(1999年最初发布,2007年开始修订更新)由美国国家心脏、肺和血液研究所高级研究员Caroline S Fox博士及约翰霍普金斯大学医学教授,Sherita Hill Golden博士共同主持编写,并于8月5日同

AHA、ADA 联合发布2型糖尿病患者心血管疾病预防的新指南

近日,美国糖尿病学会(ADA)和美国心脏协会(AHA)联合发布了新修订的成人2型糖尿病患者心血管疾病预防的科学指南 。

该指南(1999年最初发布,2007年开始修订更新)由美国国家心脏、肺和血液研究所高级研究员Caroline S Fox博士及约翰霍普金斯大学医学教授,Sherita Hill Golden博士共同主持编写,并于8月5日同时在线发表于Circulation和Diabetes Care两本杂志。

“心血管疾病是导致糖尿病患者死亡的主要原因,所以在心血管疾病的发病率和死亡率及风险管理上至关重要。这一指南为我们获得心血管疾病预防的最新信息提供了一站式的资源,”Golden教授介绍道。

钙文件总结了2008年以来发表的研究资料,以及基于这些数据不同组织制定的指南的变化。

指南主要包括以下几个方面:诊断标准方面,包括了ADA2010年推荐的采用HbA1c来诊断糖尿病;生活方式管理方面,包括体力活动和营养、体重管理、阿司匹林的使用、血糖的控制、血压的管理、血脂的管理、肾功能和心血管并发症的筛查;指南还列出了存在争议需进一步研究的领域清单。

过去8年中糖尿病管理的重大变化

Golden教授介绍道,自2007年以来,糖尿病管理方面的重大变化可以用“ABC”来说明。

2007年,人们仍然质疑进一步降低HbA1c上限(“A”)至7%以下是否更有益与心血管疾病的管理。

从2008年报告的控制糖尿病患者心血管危险行动 (ACCORD)试验研究、糖尿病和心血管病行动:百普乐与达美康缓释片对照试验以及退伍军人糖尿病试验(VADT)三大试验结果来看,并没有证据表明进一步降低HbA1c能够带来更多的益处。“因此,7%仍然只是一个目标,但是,当你专注于预防CVD时血糖就不再是主要目标了,”Golden教授说道。

基于2010年的ACCORD血压试验研究结果,糖尿病患者的推荐血压目标(“B”)近期也由原来的130/80 mmHg放宽至140/90 mmHg。该试验结果显示,130/80 mmHg的降血压目标并没有为患者带来提供进一步获益,而且由此引发的副作用增多。“我们当前设定的血压目标最适合心血管疾病的预防,”Golden教授说道。

胆固醇管理方面(“C”),最大的变化产生于2013年,AHA/ACC建议临床医生停止使用LDL作为目标,改为基于总体CVD风险给予他汀类药物治疗。

该指南,认为大多数2型糖尿病患者应接受中或大剂量他汀类药物治疗,得到了ADA的认可。

对于生活方式的改变这一部分,2013年发表的Look AHEAD试验显示,尽管密集的生活方式干预并没有减少CVD的发生,但是干预的确改善了患者的功能和生活质量,减少了糖尿病患者药物的服用。

需进一步研究的6个领域

ADA/AHA文件中还列出了需进一步研究的六个领域:

降糖药物在减少心血管事件中的作用

减重手术的作用

低血糖对心血管系统的危害

降压的最适目标

降低甘油三酯的作用

亚临床CVD的影像学评估

原始出处:

Miriam E Tucker.New US Guidelines Address CVD Prevention in Type 2 Diabetes.Medscape Medical News,August 11, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-15 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-15 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2058489, encodeId=2ffc20584896d, content=<a href='/topic/show?id=5a0f5184811' target=_blank style='color:#2F92EE;'>#心血管疾病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51848, encryptionId=5a0f5184811, topicName=心血管疾病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sun Jan 17 20:10:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923327, encodeId=4472192332e6e, content=<a href='/topic/show?id=1408583e45d' target=_blank style='color:#2F92EE;'>#新指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58374, encryptionId=1408583e45d, topicName=新指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Sun Dec 27 21:10:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264553, encodeId=60f31264553fd, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267270, encodeId=91d9126e270c4, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383177, encodeId=f0cb13831e796, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473884, encodeId=211d14e388447, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497900, encodeId=d74a149e900b3, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Sat Aug 15 07:10:00 CST 2015, time=2015-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35589, encodeId=9bc735589cb, content=这确实值得认真的学一学,领悟其中的, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 21:15:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-14 medcardio

    这确实值得认真的学一学,领悟其中的

    0

相关资讯

ADA 2015:TECOS试验将公布结果

        RuryHolman,MB,ChB        主要研究者RuryHolman,MB,ChB将报告TECOS试验(评价西格列汀的心血管结果)的结果。报告将在6月8日、星期一下午举行,每场2小时。    

ADA 2015:ELIXA试验将公布结果

        MarcPfeffer,医学博士,博士主要研究者Marc Pfeffer教授,将报告ELIXA(2型糖尿病患者发生急性冠脉综合征后、采用AVE0010(利西拉来)治疗的心血管结果)试验的结果。报告将在6月8日、星期一下午举行,每场2小时。Pfeffer和ELIXA执行委员会的成员将讨论6000例经历了急

ADA 2015:主席口头报告,8项糖尿病研究不容错过

波士顿当地时间6月9日上午10:15-12:15,第 75 届美国糖尿病学会科学年会(ADA 2015)压轴大戏——主席口头报告专场(Presidents Oral Session)上演,本专场从3000余篇原创研究摘要中精选8项研究进行口头报告,重点强调糖尿病基础和临床领域的最新研究和进展。现将上述8项研究做以简要概述:

ADA 2015:阿格列汀未增加ACS患者心血管事件(EXAMINE试验)

EXAMINE试验中有关心肌缺血事件和心血管住院率的所有数据以口头报告的形式公布。EXAMINE试验评估了近期发生急性冠脉综合征的2型糖尿病患者在接受DPP-4抑制剂阿格列汀后的心血管事件。结果显示,在EXAMINE试验人群中,心肌梗死及不稳定型心绞痛、冠脉重建、心血管事件住院以及这些缺血性事件构成的复合终点的发生率普遍较高,尤其是心血管事件住院率及冠脉重建。但以上心肌缺血事件在阿格列汀组和安慰剂

ADA 2015:SAVOR-TIMI53试验:沙格列汀未增加2型糖尿病患者癌症风险

SAVOR-TIMI53试验中有关沙格列汀对2型糖尿病患者癌症风险影响的二次分析结果以口头报告的形式公布。2.1年随访结果显示,688名患者至少罹患1种癌症,沙格列汀占47.4%、安慰剂组52.6%。沙格列汀组有53例癌症相关死亡,安慰剂59例。以上结果提示沙格列汀并不会增加SAVOR-TIMI53试验中患者癌症风险或癌症死亡风险。

Baidu
map
Baidu
map
Baidu
map